Literature DB >> 22909997

Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients.

J K Bjerregaard1, M B Mortensen, K R Schønnemann, P Pfeiffer.   

Abstract

PURPOSE: Pancreatic cancer (PC) is associated with a dismal prognosis. Few studies have examined characteristics and outcome in an unselected population-based cohort of PC patients. Therefore, we investigated patient baseline characteristics, therapy choices and survival in a complete cohort of patients with PC.
METHODS: All cases diagnosed with PC between 2007 and 2009 in the Region of Southern Denmark (pop: 1,200,000) were prospectively registered. Patient characteristics including performance status, information about haematology, liver function and therapy were retrieved from patient charts, and used to compare differently treated and untreated groups.
RESULTS: Six-hundred-eighteen cases were registered as PC; 25 of which did not have adenocarcinomas. Patients were divided in 3 clinical groups based on initial therapy; group 1: resection (n=64), group 2: chemotherapy or chemo-radiotherapy (n=191), group 3: no tumour directed therapy (n=324). Median survival (mOS) (95% confidence interval (CI)) in the three groups was 25.7 months (18-30), 8.1 months (7.0-9.5) and 1.1 months (1.0-1.3) respectively. Three percent of patients participated in clinical trials. An evaluation of baseline factors prognostic value suggested that treated patients differed significantly from non-treated patients.
CONCLUSION: This study reports survival in treated groups comparable to results obtained from clinical trials with highly selected patients. However the majority of patients with PC do not receive cancer directed therapy. This group was significantly different in several baseline factors, which could suggest a different biology. Improving the outcome of PC patients calls for research into the large group of untreated patients, as only a minority of patients receive cancer directed therapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22909997     DOI: 10.1016/j.ejca.2012.07.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Authors:  Martin Graversen; Sönke Detlefsen; Jon Kroll Bjerregaard; Per Pfeiffer; Michael Bau Mortensen
Journal:  Clin Exp Metastasis       Date:  2017-05-17       Impact factor: 5.150

Review 2.  A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs.

Authors:  A Carrato; A Falcone; M Ducreux; J W Valle; A Parnaby; K Djazouli; K Alnwick-Allu; A Hutchings; C Palaska; I Parthenaki
Journal:  J Gastrointest Cancer       Date:  2015-09

Review 3.  Pancreatic Cancer: 80 Years of Surgery-Percentage and Repetitions.

Authors:  Birgir Gudjonsson
Journal:  HPB Surg       Date:  2016-10-25

4.  Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure.

Authors:  Martin Graversen; Lars Lundell; Claus Fristrup; Per Pfeiffer; Michael B Mortensen
Journal:  Pleura Peritoneum       Date:  2018-11-27

5.  Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer.

Authors:  Sho Yasuta; Tatsushi Kobayashi; Hidetoshi Aizawa; Shinichiro Takahashi; Masafumi Ikeda; Masaru Konishi; Motohiro Kojima; Hirofumi Kuno; Katsuhiko Uesaka; Soichiro Morinaga; Atsushi Miyamoto; Hirochika Toyama; Norihisa Takakura; Keishi Sugimachi; Wataru Takayama
Journal:  BMC Cancer       Date:  2020-12-02       Impact factor: 4.430

Review 6.  Danish Pancreatic Cancer Database.

Authors:  Claus Fristrup; Sönke Detlefsen; Carsten Palnæs Hansen; Morten Ladekarl
Journal:  Clin Epidemiol       Date:  2016-10-25       Impact factor: 4.790

7.  Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis.

Authors:  Martin Graversen; Sönke Detlefsen; Jon Kroll Bjerregaard; Claus Wilki Fristrup; Per Pfeiffer; Michael Bau Mortensen
Journal:  Ther Adv Med Oncol       Date:  2018-06-01       Impact factor: 8.168

Review 8.  Molecular mediators of peritoneal metastasis in pancreatic cancer.

Authors:  Leela Rani Avula; Brendan Hagerty; Christine Alewine
Journal:  Cancer Metastasis Rev       Date:  2020-08-11       Impact factor: 9.264

9.  Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer.

Authors:  O S Bjerring; S Hess; H Petersen; C W Fristrup; L Lundell; M B Mortensen
Journal:  BJS Open       Date:  2021-03-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.